Literature DB >> 29396638

[Current aspects in the prognosis of advanced melanoma].

J Sirokay-Kohlmeyer1.   

Abstract

The therapy of metastatic melanoma has changed rapidly in recent years. Immune checkpoint blockade and targeted therapy have replaced less effective chemotherapies. New clinical studies also point towards a substantial benefit of these drugs for the adjuvant treatment of high-risk patients. Thus, the prognosis of advanced melanoma has improved. Nevertheless, it remains a life-threatening condition due to frequent relapses and progression of the disease. This article aims at providing an overview of current treatment strategies for metastasized melanoma and their impact on prognosis of the disease. In addition, changes in the recently published American Joint Committee of Cancer (AJCC) classification identifying groups at risk will be highlighted.

Entities:  

Keywords:  Adjuvant therapy; Immune checkpoint blockade; Metastasized melanoma; Recurrence; Targeted therapy

Mesh:

Substances:

Year:  2018        PMID: 29396638     DOI: 10.1007/s00105-018-4124-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  29 in total

1.  Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Authors:  Nicole Glodde; Tobias Bald; Debby van den Boorn-Konijnenberg; Kyohei Nakamura; Jake S O'Donnell; Sabrina Szczepanski; Maria Brandes; Sarah Eickhoff; Indrajit Das; Naveen Shridhar; Daniel Hinze; Meri Rogava; Tetje C van der Sluis; Janne J Ruotsalainen; Evelyn Gaffal; Jennifer Landsberg; Kerstin U Ludwig; Christoph Wilhelm; Monika Riek-Burchardt; Andreas J Müller; Christoffer Gebhardt; Richard A Scolyer; Georgina V Long; Viktor Janzen; Michele W L Teng; Wolfgang Kastenmüller; Massimiliano Mazzone; Mark J Smyth; Thomas Tüting; Michael Hölzel
Journal:  Immunity       Date:  2017-10-17       Impact factor: 31.745

Review 2.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

3.  No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.

Authors:  M Sladden; S Zagarella; C Popescu; M Bigby
Journal:  Br J Dermatol       Date:  2015-03       Impact factor: 9.302

4.  Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.

Authors:  Tobias Bald; Jennifer Landsberg; Dorys Lopez-Ramos; Marcel Renn; Nicole Glodde; Philipp Jansen; Evelyn Gaffal; Julia Steitz; Rene Tolba; Ulrich Kalinke; Andreas Limmer; Göran Jönsson; Michael Hölzel; Thomas Tüting
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

5.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

Review 6.  Chemotherapy for Melanoma.

Authors:  Melissa A Wilson; Lynn M Schuchter
Journal:  Cancer Treat Res       Date:  2016

7.  The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

Authors:  Alexander M M Eggermont; Reinhard Dummer
Journal:  Eur J Cancer       Date:  2017-09-29       Impact factor: 9.162

8.  Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson
Journal:  CA Cancer J Clin       Date:  2017-10-13       Impact factor: 508.702

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

Review 10.  Implementation and utilization of the molecular tumor board to guide precision medicine.

Authors:  Shuko Harada; Rebecca Arend; Qian Dai; Jessica A Levesque; Thomas S Winokur; Rongjun Guo; Martin J Heslin; Lisle Nabell; L Burt Nabors; Nita A Limdi; Kevin A Roth; Edward E Partridge; Gene P Siegal; Eddy S Yang
Journal:  Oncotarget       Date:  2017-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.